Skin of Color Symposium: Dermatology Pearls for Treating Pediatric Patients of Color
Pediatric patients with melanin-rich skin, or skin of color (SOC), can be disproportionately affected by numerous dermatologic conditions. Patients can be more susceptible or have a greater disease burden, especially with conditions such as acne, atopic dermatitis, psoriasis, pigmentary disorders, and hair disorders. Patients of color from all races and backgrounds including, but not limited to, those of African, Caribbean, Hispanic, LatinX, and Asian descent may present with dermatologic disorders differently from Caucasian patients and may require specific considerations for optimal treatment.
It is important that clinicians are not only aware of these disparities across multiple disease states, but that they are aware of changes to practice that need to be made. The Skin of Color Symposium, originally presented in a live symposium at the Masters of Pediatric Dermatology (MOPD) 2022 meeting is a 1.75-hour session solely centered upon caring for dermatologic issues in pediatric patients with skin of color (SOC). Provided in partnership with the Skin of Color Society, the Pediatric Skin of Color Symposium is designed to address these gaps in dermatologic care for pediatric SOC patients by reviewing skin conditions prevalent in SOC patients or those which disproportionately burden SOC patients and strategies for practicing cultural sensitivity when treating patients and communicating with caregivers. Participants will gain education needed to better treat these conditions and modify current practices to accommodate the needs of patients with darker pigmented skin.
Target Audience
This activity is designed for an audience of physicians, nurses and professional staff members of medical practices specializing in dermatology, pediatric dermatology, plastic surgery, cosmetic surgery and other dermatologic medical procedures.
Learning Objectives
- Describe the impact of vitiligo in patients with darker pigmented skin and implications for managing vitiligo in this setting
- Review current and emerging treatment options for vitiligo patients as well as nuances to treatment for pediatric SOC patients
- Recognize how to diagnose acne in patients with skin of color
- Review current and emerging treatments for acne patients, including recommendations for treating the pediatric SOC patient population
- Recognize how to diagnose AD in patients with skin of color
- Review current and emerging treatments for AD patients, including recommendations for treating the pediatric SOC patient population
- Recognize how to diagnose psoriasis in patients with skin of color
- Review current and emerging treatments for psoriasis patients, including recommendations for treating the pediatric SOC patient population
- Cultural Sensitivity - Latanya T. Benjamin, MD, FAAD, FAAP
- Discuss why it is important for clinicians to employ cultural sensitivity when caring for patients and communicating with caregivers, as well as strategies for applying this to everyday practice
- Hair Issues in Children of Color - Candrice R. Heath, MD
- Review hair issues, such as traction alopecia and other forms of hair loss, commonly seen in children of color and nuances to treatment
- Inflammatory Skin Disorders: AD and Psoriasis - Latanya T. Benjamin, MD, FAAD, FAAP
- Discuss issues with diagnosing inflammatory skin disorders in SOC patients
- Review available treatments and nuances to treatment specifically for SOC patients
- Acne and Pigment Issues - Candrice R. Heath, MD
- Discuss issues post-inflammatory hyperpigmentation as a result of acne that especially burden patients with darker pigmented skin
- Review available treatments and nuances to treatment specifically for SOC patients
- Treatment Update for Pigmentary Disorders - Latanya T. Benjamin, MD, FAAD, FAAP
- Review pigmentary disorders that disproportionately affect patients of color and subsequent treatment options
- Dermatologic Issues in LatinX Patients - Mercedes E. Gonzalez, MD
- Highlight challenges faced by the pediatric LatinX patient population and their clinicians in terms of increased disease burden and challenges in treating these disorders
- Panel Discussion/Q&A - Latanya T. Benjamin, MD, FAAD, FAAP, Mercedes E. Gonzalez, MD, Candrice R. Heath, MD, Robin Straus, MD
- All faculty from the symposium join for a panel discussion and take questions from the attendees at the live symposium
Latanya T. Benjamin, MD, FAAD, FAAP
Associate Professor of Dermatology
Florida Atlantic University
Boca Raton, FL
Mercedes E. Gonzalez, MD
Medical Director
Pediatric Dermatology of Miami
Miami, FL
Candrice R. Heath, MD
Assistant Professor of Dermatology
Lewis Katz School of Medicine
Temple University
Philadelphia, PA
Disclosures
NAME | RELATIONSHIP | COMPANY |
---|---|---|
Latanya Benjamin, MD | Speaker's Bureau | Sanofi and Regeneron Pharmaceuticals, Inc. |
Mercedes Gonzalez, MD | Advisor | Nobelpharma, CeraVe |
Researcher | AbbVie, Inc., Dermavant, Pfizer, Verrica, Novan, Arcutis, Eli Lilly/Dermira, Krystal Biotech, Regeneron Pharmaceuticals | |
Speaker | Regeneron/Sanofi Genzyme, Pfizer | |
Candrice Heath, MD | Consultant | Cassiopea, Pfizer, LEO, CeraVe, Johnson & Johnson, Arcutis |
Credit provided by AKH Inc., Advancing Knowledge in Healthcare In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and Tarsus Cardio dba LiVDerm. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Physician AKH Inc., Advancing Knowledge in Healthcare designates this enduring material activity for a maximum of 1.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Nurse 1.75 ANCC contact hours Physician Assistant AKH Inc., Advancing Knowledge in Healthcare has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.75 AAPA Category 1 CME credits. Approval is valid until October 20, 2023. PAs should only claim credit commensurate with the extent of their participation. Commercial Support |
Disclosure
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.
Latanya Benjamin, MD | Speaker's Bureau | Sanofi and Regeneron Pharmaceuticals |
Mercedes Gonzalez, MD | Advisor | |
Researcher | AbbVie, Inc., Dermavant, Pfizer, Verrica, Novan, Arcutis, Eli Lilly/Dermira, Krystal Biotech, Regeneron Pharmaceuticals | |
Speaker | Regeneron/Sanofi Genzyme, Pfizer | |
Candrice Heath, MD | Consultant | Cassiopea, Pfizer, LEO, CeraVe, Johnson & Johnson, Arcutis |
Michelle Bielarski, RN | N/A | |
Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.
Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Available Credit
- 1.75 AAPA Category I CME
- 1.75 AMA PRA Category 1 Credit™
- 1.75 ANCC
- 1.75 Participation
Required Hardware/software
A computer with an internet connection
Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
Other additional software may be required such as PowerPoint or Adobe Acrobat Reader.
AKH Privacy Policy (link: https://akhcme.com/akhcme/pages/privacy